Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InMed Pharmaceuticals (INM) EBITDA (2021 - 2025)

InMed Pharmaceuticals (INM) has 5 years of EBITDA data on record, last reported at -$2.1 million in Q4 2025.

  • For Q4 2025, EBITDA rose 6.21% year-over-year to -$2.1 million; the TTM value through Dec 2025 reached -$7.9 million, changed 0.44%, while the annual FY2025 figure was -$7.9 million, 3.1% up from the prior year.
  • EBITDA reached -$2.1 million in Q4 2025 per INM's latest filing, down from -$1.8 million in the prior quarter.
  • Across five years, EBITDA topped out at -$472234.0 in Q2 2023 and bottomed at -$7.9 million in Q2 2022.
  • Average EBITDA over 5 years is -$2.6 million, with a median of -$2.1 million recorded in 2022.
  • Peak YoY movement for EBITDA: skyrocketed 94.0% in 2023, then tumbled 329.61% in 2024.
  • A 5-year view of EBITDA shows it stood at -$4.3 million in 2021, then surged by 50.94% to -$2.1 million in 2022, then rose by 22.39% to -$1.6 million in 2023, then plummeted by 37.47% to -$2.2 million in 2024, then rose by 6.21% to -$2.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA were -$2.1 million in Q4 2025, -$1.8 million in Q3 2025, and -$1.8 million in Q2 2025.